|
市场调查报告书
主要企业：骨质疏松症 - 竞争的扩大威胁大型企业和促进技术创新
Key Companies: Osteoporosis - Growing competition threatens leading franchises and drives innovation
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品编码 |
207802 |
| 内容信息 |
英文 Pages: 34 |
| 价格 |
|
|
主要企业：骨质疏松症 - 竞争的扩大威胁大型企业和促进技术创新 是由出版商Datamonitor在2011年11月所出版的。
这份英文市场调查报告书包含Pages: 34 价格从美金3800起跳。
骨质疏松症治疗市场为具备实施大型临床实验的资金与网罗领域整体销售力的大型药厂所寡占的状态。在针对骨质疏松症的行动上，投入1～2种类的药剂产品至市场，宣传其安全性和对病患的便利性，以达到适应症扩大，为一般的企业策略。
本报告，汇整骨质疏松症治疗市场相关主要企业的品牌生命周期以及产品组合管理策略的彻底考察、Merck & Co.以及Servier公司的骨质疏松症产品组合管理策略与其课题的事例研究、活跃于该领域的企业策略动向、近年的重要授权契约的影响、大型企业以及其2005-2010年的业绩、今后的商机与课题的对应等最新的调查情报，由下列摘要形式阐述。
概要
报告摘要
- 策略的范围以及重点
- Datamonitor的主要见解
- 相关报告
企业策略
- 策略概要
- 企业策略的趋势
- 发展合成代谢治疗成为市场的最优先事项
- 药品重制为普遍的延长品牌寿命策略
- 适应症扩大增加骨质疏松症治疗药物的市场性
- 多角化治疗的导入可增加收益与降低风险
- 品牌的独特卖点「投药的便利性」
- 策略合作・协议的最新情报
- Nycomed增强武田药品的骨质疏松症产品组合
- Warner Chilcott的妇产科专门技术将协助建立于骨质疏松症市场上的地位
MERCK & CO.
- 企业策略
- 骨质疏松症产品组合评价
- MERCK & CO.骨质疏松症产品组的SWOT分析
LES LABORATOIRES SERVIER
- 企业策略
- 骨质疏松症产品组合评价
- SERVIER公司骨质疏松症产品组的SWOT分析
其他大型企业的产品组合评价
- Novartis
- Amgen
- Pfizer
- Eli Lilly
- GlaxoSmithKline
参考文献一览
附录
图表
Description
Introduction
The osteoporosis market is dominated by large pharmaceutical companies that can leverage their considerable financial reserves to conduct large-scale clinical trials, and which have the marketing strength needed to penetrate this sector. Osteoporosis companies market one or two drugs for which they promote safety and patient convenience, and pursue indication expansions.
Features and benefits
- In-depth discussion of brand lifecycle and portfolio management strategies of key companies involved in the osteoporosis market.
- Review Merck & Co.'s and Servier's osteoporosis portfolio management strategies and what challenges these companies are facing.
- Assess trends in corporate strategies of companies active in the osteoporosis arena and understand the impact of key recent licensing deals.
- Identify the leading companies involved in osteoporosis and how their franchises have been performing over 2005-10.
- Learn how companies can respond to future opportunities and challenges in the field.
Highlights
- Developing new technologies to improve compliance remains a popular portfolio management strategy in the osteoporosis market and the latest opportunity is for more conveniently dosed and administered anabolic drugs.
- Merck lost its market leading position due to generic erosion. With two novel therapies in development, the company now has an opportunity to restore its market share. However, the main challenge is to bring these drugs to market while maintaining relationships with key osteoporosis stakeholders.
- Servier has so far maintained a successful standing in Europe by promoting Protelos (strontium ranelate) as a novel effective and safe alternative therapy to bisphosphonates. However, in spite of the possible launch of a follow-on product, long term growth prospects will be hindered by future competition from generic strontium ranelate.
Your key questions answered
- Which are the leading companies in the osteoporosis market?
- How successful are the portfolio management strategies most widely used in the osteoporosis market?
- How is Merck & Co. attempting to regain its leading position?
- What makes Servier's osteoporosis offering unique?
- What are the main challenges companies are facing in this therapy area?
TOC
Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
OVERVIEW
COMPANY STRATEGIES
- Strategic overview
- Trends in corporate strategy
- Developing anabolic treatments becomes a priority in the market
- Reformulations are popular brand lifecycle extension strategies
- Indication expansions increase the market potential of osteoporosis drugs
- Multiple therapy offerings can increase returns and lower risk
- Dosing convenience as a unique selling point of their brands
- Recent strategic partnerships and deals
- Nycomed bolsters Takeda's osteoporosis portfolio
- Warner Chilcott's women's health expertise will help build its presence in the osteoporosis market
MERCK & CO.
- Corporate strategy
- Osteoporosis portfolio assessment
- Merck loses its market leading position due to poor portfolio management strategy
- High risk first-in-class pipeline products will reward Merck
- SWOT analysis for Merck's osteoporosis portfolio
LES LABORATOIRES SERVIER
- Corporate strategy
- Osteoporosis portfolio assessment
- Servier promotes safety data to exploit concerns regarding other therapies
- Servier in-licenses NBS101 to maintain its osteoporosis franchise but this is unlikely to be sufficient
- Servier shows commitment to the European osteoporosis community
- SWOT analysis for Servier's osteoporosis portfolio
PORTFOLIO REVIEW OF OTHER LEADING COMPANIES
- Novartis
- Continued interest in the market is reflected in the pipeline activity
- Amgen
- Investing heavily in building its presence in the osteoporosis community to drive Prolia's uptake
- Amgen is developing a novel anabolic compound
- Pfizer
- Pfizer attempts to redefine the SERM market
- Eli Lilly
- Eli Lilly to lose leading position due to poor pipeline
- GlaxoSmithKline
- GlaxoSmithKline maintains interest in the osteoporosis market
BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
APPENDIX
- PharmaVitae Explorer database
- Conferences attended
- Report methodology
|
